| Q35423470 | 5-aza-2'-deoxycytidine activates iron uptake and heme biosynthesis by increasing c-Myc nuclear localization and binding to the E-boxes of transferrin receptor 1 (TfR1) and ferrochelatase (Fech) genes. |
| Q33332587 | A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer |
| Q24170503 | Aberrant gene expression in human non small cell lung carcinoma cells exposed to demethylating agent 5-aza-2 '-deoxycytidine |
| Q35348043 | Cancer epigenetics: linking basic biology to clinical medicine. |
| Q36466174 | Carcinogenicity and haemoglobin synthesis induction by cytidine analogues |
| Q39139055 | CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors |
| Q40997606 | Decitabine maintains hematopoietic precursor self-renewal by preventing repression of stem cell genes by a differentiation-inducing stimulus |
| Q36284232 | Decitabine: a historical review of the development of an epigenetic drug |
| Q33407030 | Decitabine: a review of its use in older patients with acute myeloid leukaemia |
| Q33678040 | Demethylating Agents in the Treatment of Cancer |
| Q35750354 | Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine |
| Q35742564 | Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia |
| Q37381606 | Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. |
| Q35825522 | Emerging therapies in hematopoietic stem cell transplantation |
| Q33621141 | Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. |
| Q33863567 | Epigenetic therapies in MDS and AML |
| Q38112417 | Epigenetic therapy in allogeneic hematopoietic stem cell transplantation |
| Q26745709 | Epigenetic therapy in gastrointestinal cancer: the right combination |
| Q38332497 | Epigenetic therapy of cancer stem and progenitor cells by targeting DNA methylation machineries |
| Q37184917 | Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias |
| Q37964702 | Epigenetic-based therapies in cancer: progress to date |
| Q36914167 | Gamma interferon and 5-azacytidine cause transcriptional elevation of class I major histocompatibility complex gene expression in K562 leukemia cells in the absence of differentiation |
| Q37099599 | Gene Expression and Methylation Pattern in HRK Apoptotic Gene in Myelodysplastic Syndrome |
| Q38529787 | Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer |
| Q37098221 | Induction of acute lymphocytic leukemia differentiation by maintenance therapy |
| Q92382685 | Influence of demethylation on regulatory T and Th17 cells in myelodysplastic syndrome |
| Q36416358 | Is targeted therapy feasible in acute myelogenous leukemia? |
| Q36412709 | Low concentrations of 5-aza-2'-deoxycytidine induce breast cancer stem cell differentiation by triggering tumor suppressor gene expression |
| Q33861150 | Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia |
| Q33391089 | Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study |
| Q26851510 | New answers to old questions from genome-wide maps of DNA methylation in hematopoietic cells |
| Q38172875 | Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome |
| Q43247519 | Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. |
| Q38155455 | Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments |
| Q39331564 | Selected drugs with reported secondary cell-differentiating capacity prime latent HIV-1 infection for reactivation |
| Q33847891 | Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target |
| Q37060639 | The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome |
| Q37765469 | Therapy with azanucleosides for myelodysplastic syndromes |
| Q41966277 | Transbuccal delivery of 5-aza-2 -deoxycytidine: effects of drug concentration, buffer solution, and bile salts on permeation |
| Q36890276 | p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia. |
| Q36848202 | p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies |